- Tags: dry eye
Research
Dry eye may indicate early signs of autoimmune disease
Study findings suggest ocular surface symptoms may precede systemic autoimmune diagnosis by several years.
Events
Dry Eye Institute to host immersive education retreat in Dublin
Dry eye education program's first-ever global expansion offers four days of customized, interactive learning and COPE-accredited CE.
Pipeline
FDA issues third CRL to Aldeyra, rejecting reproxalap NDA
Agency notes a lack of substantial evidence, failure to demonstrate efficacy, and inconsistent study results in latest dismissal of the DED eye drop.
Products
TearRestore launches OneDrop for daily dry eye care
Artificial tear is formulated with a preservative-free-based nanoemulsion engineered to mimic and reinforce all three layers of the natural tear film.
Business
CSI Dry Eye Innovations unveils new branding and software patent
Rebrand paves way for potential future dry eye product launches to join its flagship, AI-based program: CSI Dry Eye Software.
Pipeline
Novartis's ianalumab earns FDA Breakthrough Therapy designation for Sjögren’s disease
Fully human monoclonal antibody is delivered as a monthly subcutaneous injection; company plans to submit for global approval in early 2026.
Products
OCuSOFT launches Retaine Omega Forte for dry eye
New nutritional supplement offers a daily dose of omega-3 essential fatty acids.
Events
Registration now open for Eyes On Dry Eye 2026
Largest virtual dry eye event of the year offers up to 7 hours of free CE from leading clinical experts.
Products
Focus Vitamins launches PF artificial tears for dry eye
Manufactured by cGMP- and NSF-certified suppliers, Focus Tears PF Eye Drops are formulated with CMC sodium 0.5% to offer temporary ocular relief.Pipeline
FDA extends reproxalap's PDUFA to March 2026
Updated target action date applies to Aldeyra’s third NDA submission of the investigational DED eye drop.
Products
Scope's OPTASE HYLO Forte Dry Eye Drops offer long-lasting symptom relief
Clinical experts share OD-MD insights into the advanced artificial tears’ hydrating PF formulation with active glycerin and hyaluronic acid.
Pipeline
Azura gets positive FDA feedback on NDA submission for MGD ointment
Positive pre-NDA meeting for selenium sulfide ointment precedes planned phase 3 data release in Q1 2026 and regulatory submission in H2 2026.
Products
Amneal receives FDA approval for Restasis generic
Generic version of Allergan’s cyclosporine ophthalmic emulsion 0.05% eye drop for dry eye is the second to receive U.S. regulatory clearance.
Research
The Dry Eye Society of the Americas launches as new nonprofit
Founded by leading dry eye specialists, DESA intends to establish dry eye as a recognized subspecialty.
Research
Eyelid irrigating retractor achieves ocular lavage for allergic conjunctivitis
Case study supports use of Rinsada in-office for its additive effect in targeting the beginnings of the allergy cascade to help treat the entire ocular surface.
Research
Phase 3b data supports superior tear response with TRYPTYR
Presented at AAO, new findings stem from measuring tear volume produced following administration of the DED drop.
Products
Topcon launches dry eye imager with robotic intelligence
TERA is a multimodal platform for detecting, grading, and managing DED—and pairs robotic automation with high-res imaging for standardized testing.
Research
New data reinforces XIIDRA's eye dryness relief among CL wearers
Open-label study evaluated effectiveness of lifitegrast 5%, noting significant improvements in end-of-day dryness and discomfort in just 2 weeks.
Products
Scope introduces OPTASE HYLO FORTE dry eye drops
Artificial tear is formulated with active glycerin for moderate-to-severe dry eye disease, offering extra moisture and a protective cushion for long-lasting relief.
Research